[March 20, 2013]

Research and Markets: Truvada (HIV) - Forecast and Market Analysis to 2022

Research and Markets (http://www.researchandmarkets.com/research/qhj2hs/truvada_hiv) has announced the addition of the "Truvada (HIV) - Forecast and Market Analysis to 2022" report to their offering.

GlobalData has released its new PharmaPoint Drug Evaluation report, Truvada (HIV) - Forecast and Market Analysis to 2022. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by liiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

Gilead's Truvada is a fixed-dose combination of two NRTIs, Emtriva (emtricitabine/FTC) and Viread (tenofovir disoproxil fumarate/TDF (News - Alert)), and it is indicated for anti-HIV therapy in combination with other antiretroviral agents (e.g., NNRTIs or PIs). The mechanism of action of Truvada involves the following (Truvada prescribing information, 2012).

Scope

- Overview of HIV, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.

- Detailed information on Truvada including product description, safety and efficacy profiles as well as a SWOT analysis.

- Sales forecast for Truvada for the top nine countries from 2012 to 2022.

- Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil and China

Key Topics Covered:

1 List of Tables and Figures

2 Introduction

3 Disease Overview

4 Disease Management

5 Competitive Assessment

6 Truvada (tenofovir disoproxil fumarate/emtricitabine)

7 Appendix

For more information visit http://www.researchandmarkets.com/research/qhj2hs/truvada_hiv

[ InfoTech Spotlight's Homepage ]